| Document |
Document Title |
|
WO/2023/234407A1 |
An oral vaccine composition against a porcine circovirus-related disease, the oral vaccine composition comprising a pupa or a cell of a baculovirus infectious insect that has been subjected to an infection treatment with a recombinant ba...
|
|
WO/2023/234954A1 |
The present invention relates to the treatment of melanoma in a patient, where the method includes administering to a patient who has or is suspected of having melanoma a therapeutically effective amount of tebentafusp; and a therapeutic...
|
|
WO/2023/235298A1 |
The disclosure provides methods for reducing a thermal start-up burst release from an implantable device for controlled release of a therapeutic agent from a device comprising a capsule configured for implantation and having a reservoir....
|
|
WO/2023/231659A1 |
Provided are a protein composition comprising lactoferrin and/or osteopontin in a weight ratio of 2:1, and use thereof in preparing an anti-enterovirus 71 drug or functional product.
|
|
WO/2023/235522A1 |
Described herein are compositions and methods for selective depletion of an EGFR target molecule using a recyclable receptor-binding mediated complex to elicit uptake or endocytosis and cellular degradation of the target molecule. Exempl...
|
|
WO/2023/232984A1 |
The present invention pertains to an S100A1 protein, a biologically active fragment or variant thereof, to a nucleic acid encoding said S100A1 protein or said biologically active fragment or variant thereof, to a vector comprising said n...
|
|
WO/2023/231931A1 |
Disclosed in the present invention is a red light-regulated transcriptional activation device/system (referred to as an REDLIP device/system) for mammals, which comprises a red light photosensitive protein element, a transcriptional acti...
|
|
WO/2023/231573A1 |
An isomer of a peptide derivative of formula (I), a mixture of stereoisomers thereof, or a salt thereof, or a composition thereof, and the use thereof. The isomer of the peptide derivative of formula (I) and the composition containing th...
|
|
WO/2023/232022A1 |
The present application provides a recombinant fusion protein, comprising 1) a PD-L1 antibody or an antigen-binding fragment thereof, and 2) a VEGF-binding peptide, the N-terminus of a heavy chain or a light chain of the PD-L1 antibody o...
|
|
WO/2023/235718A2 |
Methods of treating cardiac hypertrophy or cardiomyocyte hypertrophy, or methods of inhibiting progression of heart failure in a subject in need thereof, in which the methods comprise administering a pharmaceutical composition comprising...
|
|
WO/2023/233665A1 |
Provided are: an immunocyte activator containing, as an active ingredient, a substance which inhibits the binding of fibronectin and an immunosuppressive receptor LILRB4; and a therapeutic agent for immunocyte-related inflammatory diseas...
|
|
WO/2023/231969A1 |
The present invention belongs to the field of protein engineering, and relates to a hybrid peptide formed by a chymotrypsin inhibitory peptide and insulin or an analogue thereof. The heterozygous insulin analogue can resist the degradati...
|
|
WO/2023/235109A1 |
The invention provides novel compounds that are potent inhibitors of main protease (MPro) and pharmaceutical compositions and methods thereof for treating MPro-associated or mediated diseases and conditions, such as severe acute respirat...
|
|
WO/2023/235648A1 |
Methods and compositions for nuclear delivery and transcriptional repression employ a cell-penetrant MeCP2 fusion protein.
|
|
WO/2023/234143A1 |
The virus vector according to the present invention is formed such that a full length cDNA with a stop codon of Kras is introduced into the first exon of Kras of a human cell genome DNA, in order to provide a virus vector capable of inhi...
|
|
WO/2023/235453A1 |
This document relates to methods and materials for modulating (e.g., reducing) T cell activation (e.g., T cell proliferation, T cell effector functions, and/or cytokine secretion) using a TRAILshort polypeptide, a variant TRAILshort poly...
|
|
WO/2023/235319A1 |
Glycosylated, cyclic peptides of Formula (I): A1-cyclo[A2-A3-A4-A5]-A6-O-Carb, Formula (II): A1-cyclo[A5-A3-A4-A2]-A6-O-Carb, and pharmaceutically acceptable salts thereof, are described herein, which are useful, e.g., in treating pain. ...
|
|
WO/2023/235776A2 |
The present disclosure provides methods of treating cancer in a subject in need thereof, the method comprising contacting a cellular surface on the subject with an effective amount of a recombinant collagen fragment, including a fragment...
|
|
WO/2023/231730A2 |
The present invention belongs to the field of medicine, and specifically relates to a treatment method using mazdutide. The present invention provides a method for preventing or treating overweight and obesity, and a method for improving...
|
|
WO/2023/233034A1 |
The present invention generally relates to the field of recombinant gene expression in host cells. In particular, the invention relates to a recombinant human myeloid-derived growth factor (MYDGF) protein that exhibits a minimal degree o...
|
|
WO/2023/231052A1 |
A nutritional polypeptide having a branched structure and efficient broad-spectrum antibacterial and antifungal functions. The nutritional polypeptide having the branched structure is a polymer peptide which has a molecular weight of 300...
|
|
WO/2023/231942A1 |
The present application provides a pharmaceutical composition, comprising an anti-CLDN18.2 antibody-drug conjugate, a buffer, a stabilizer, and a surfactant. The present application further provides a method for preparing the pharmaceuti...
|
|
WO/2023/235724A1 |
Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucagon-like peptide-1 (GLP-1) and glucagon (Gcg) co-...
|
|
WO/2023/235553A1 |
Disclosed are methods of treating hemorrhagic shock, for example hemorrhagic shock associated with traumatic injury, gastrointestinal bleeding, spontaneous hemorrhage due to hematologic disorders, uterine hemorrhage, and combinations the...
|
|
WO/2023/288283A9 |
The present disclosures relates to methods of use to the use of interleukin-2 (IL2) muteins, pharmaceutical formulations thereof, methods useful in the treatment of human disease in combination with adoptive cell therapy. In particular, ...
|
|
WO/2023/234703A1 |
The present invention provides a novel peptide derivative containing a specific D-amino acid and a pharmaceutical composition for preventing, ameliorating, or treating ophthalmic diseases comprising same. The peptide derivative of the pr...
|
|
WO/2023/233394A1 |
The present invention relates to a fibrillar hydrogel comprising an aqueous solution and substantially aligned fibrils composed of collagen and at least one proteoglycan, having viscoelastic characteristics enabling its use in a wide ran...
|
|
WO/2023/234673A1 |
The present invention relates to an antimicrobial peptide carrier, a fabrication method therefor, and an antimicrobial composition containing same, wherein the carrier can efficiently deliver antimicrobial peptides and induce the express...
|
|
WO/2023/232048A1 |
Disclosed are a compound of general formula (I), and a stereoisomer and a cis-trans isomer thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and R15 are as defined in the present disclosure.
|
|
WO/2023/235232A2 |
Glycosylated, cyclic peptides of Formula (I): A1-cyclo[A2-A3-A4-A5]-A6-O-Carb, Formula (II): A1-cyclo[A5-A3-A4-A2]-A6-O-Carb, and pharmaceutically acceptable salts thereof, are described herein, which are useful, e.g., in treating pain. ...
|
|
WO/2023/231433A1 |
Provided are long-acting Exendin-9-39 and a use thereof as a GLP-1 receptor antagonist in hypoglycemia treatment and preparation of a drug for treating hypoglycemia. The long-acting Exendin-9-39 comprises AR-GLP1R-01 and AR-GLP1R-02, AR-...
|
|
WO/2023/232810A1 |
The present invention relates generally to the field of anti-cancer therapy and autoimmune therapy, in particular to the use of adoptive T cell transfer therapy. More specifically, the present invention relates to compositions, pharmaceu...
|
|
WO/2023/235302A1 |
The disclosure provides devices and methods for sustained release of a therapeutic agent, the device comprising: a capsule configured for implantation and having a reservoir; a nanoporous membrane with a plurality of pores attached to th...
|
|
WO/2023/232781A1 |
The present invention relates to formulations of amylin analogues, and their use, for example, in the treatment of obesity and metabolic disorders such as diabetes. In particular, the present invention relates to stable aqueous liquid fo...
|
|
WO/2023/231778A1 |
Provided are a transgenic expression cassette capable of treatment of mucopolysaccharidosis type IIIA, an application thereof, an optimized nucleic acid molecule encoding N-sulfoglucosamine sulfohydrolase (SGSH), a designed and optimized...
|
|
WO/2023/234426A1 |
Provided is a more useful antitumor drug that is the result of further advancing conventional antibody-drug conjugates. An antibody-multidrug conjugate represented by general formula (I): [in the formula, the symbols have the meanings se...
|
|
WO/2023/235377A1 |
A recombinant interleukin-27 (IL27) expressing virus is described. The recombinant IL27 expressing virus comprises an oncolytic virus comprising one or more exogenous nucleic acid sequences capable of expressing in IL27 protein or a biol...
|
|
WO/2023/233008A1 |
The present invention relates to a hydrolyzed collagen formulation for use in decreasing blood glucose. The hydrolyzed collagen is obtained by enzymatic hydrolysis of a collagen- containing material with a combination of enzymes comprisi...
|
|
WO/2023/231048A1 |
A non-toxic polycation polymer carrier material. The polycation polymer carrier material is water-soluble hyperbranched polylysine with the molecular weight of 5000-6000 g/mol and can be used as a transfer carrier of various functional m...
|
|
WO/2023/235790A1 |
The present disclosure relates to recombinant polypeptides and uses thereof for treating, preventing, and detecting inflammatory diseases. Specifically, the disclosure provides a recombinant polypeptide comprising an IL-2 polypeptide, a ...
|
|
WO/2023/234809A1 |
The invention relates to a method for preventing iodine radionuclide damage to the human or animal body. A bound form of 4-hydroxy 3,5-diiodophenyl-containing compounds, for example within protein or peptide molecules, is introduced oral...
|
|
WO/2023/235422A2 |
Compositions and methods for making and using engineered myeloid cells that express a chimeric fusion protein for immunotherapy and compositions and methods for making and using engineered T cells that express a chimeric antigen receptor...
|
|
WO/2023/234701A1 |
The present invention relates to a composition for the prevention or treatment of retinal or macular diseases, the composition comprising: a polypeptide including an amino acid sequence with at least 70% sequence identity with that of TA...
|
|
WO/2023/235795A2 |
The present disclosure relates to the treatment of respiratory or pulmonary diseases or disorders with granulocyte-macrophage colony-stimulating factor.
|
|
WO/2023/235568A1 |
The present disclosure is directed to a method of producing human gastric insulin-secreting (GINS) cells and human gastric insulin-secreting (GINS) organoids. The present disclosure provides a population of human gastric insulin-secretin...
|
|
WO/2023/235549A1 |
Disclosed are methods of treating sepsis in an individual in need thereof via administration of a therapeutically effective amount of a humanin protein, or an analog thereof, to the individual. In one aspect, the methods may comprise adm...
|
|
WO/2023/235856A1 |
Apoptosis-resistance immune cells that express a chimeric antigen receptor such as a major histocompatibility complex-based chimeric receptor are designed for targeting and kill pathogenic immune cells such as autoreactive T cells. The a...
|
|
WO/2023/231322A1 |
Provided are a microneedle formulation, a microneedle patch and preparation methods therefor. The microneedle formulation is composed of the following components in percentage by mass: 15-55% of a microneedle framework material, 0.05-5% ...
|
|
WO/2023/207574A9 |
Provided is a fusion protein, comprising: a transferrin-binding protein, and arylsulfatase A (ARSA) or a functional active fragment thereof. The transferrin-binding protein comprises a polypeptide, an antibody or an antigen-binding fragm...
|
|
WO/2023/235490A1 |
Disclosed herein are methods of treating a subject for a condition associated with insufficient insulin secretion by administering to a subject in need of treatment for a condition associated with an insufficient level of insulin secreti...
|
